Financings

Bind Biosciences Inc. raised $47 million in a Series D round, with Rusnano joining the syndicate.

NewLink Genetics Corp. set terms for its planned $61 million initial public offering.

Selecta Biosciences Inc. raised $47 million in a Series D round, with Rusnano joining the syndicate.

Deals

Adolor Corp. is being acquired by Cubist Pharmaceuticals Inc. for $415 million.

DuoCort Pharma AB inked a $165 million adrenal insufficiency deal with ViroPharma Inc.

Dynavax Technologies Corp. expanded its Toll-like receptor inhibitor deal with GlaxoSmithKline plc.

Gilead Sciences Inc. licensed cobicistat to Bristol-Myers Squibb Co. for use in an HIV combo pill.

GlobeImmune Inc. licensed its Phase I hepatitis B vaccine to Gilead Sciences Inc.

Intrexon Corp. acquired antibody specialist Immunologix Inc. for an undisclosed sum.

Portola Pharmaceuticals Inc. licensed its Syk inhibitor program to Biogen Idec Inc. for $553 million.

. . . And More

BioWorld Today has coverage of the BIO Investor Forum; the Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS); and BioNJ, Delaware Bio and Pennsylvania Bio's Biotech 2011 .

AMAG Pharmaceuticals Inc. shareholders voted down the merger with Allos Therapeutics Inc.

Amsterdam Molecular Therapeutics NV's Glybera (alipogene tiparvovec) got a negative CHMP review.

Biogen Idec Inc. reported good data from the second Phase III trial of BG-12 (dimethyl fumarate).

Eli Lilly and Co. is withdrawing shock drug Xigris [drotrecogin alfa (activated)] after a failed study.

Exelixis Inc.'s cabozantinib met its endpoints in a Phase III medullary thyroid cancer trial.

ImmuPharma plc pulled out of its $500 million lupus deal with Cephalon Inc.

Newron Pharmaceuticals SpA's Parkinson's drug safinamide was dumped by Merck Serono SA.

Onyx Pharmaceuticals Inc. and Bayer AG got good Phase III data for regorafenib in colorectal cancer.